Learn More
e21032 Background: KRAS mutation testing is now mandatory to select patients with metastatic CRC for treatment with anti-EGFR antibodies such as cetuximab and panitumumab. Multiple studies have shown(More)
Epidermal growth factor receptor (EGFR) gene mutations identify patients withnon-small cell lung cancer (NSCLC) who have a high likelihood of benefitingfrom treatment with anti-EGFR tyrosine kinase(More)
  • 1